Abstract:PURPOSE:Reprogrammed lipid metabolism is a hallmark of cancer that provides energy, materials, and signaling molecules for rapid cancer cell growth. Cancer cells acquire fatty acids primarily through de novo synthesis and uptake. Targeting altered lipid metabolic pathways is a promising anticancer strategy. However, their regulators have not been fully investigated, especially those targeting both synthesis and uptake.METHODS:Immunohistochemistry was performed on samples from patients with hepatocellular carcinoma (HCC) to establish the correlation between miR-3180, stearoyl-CoA desaturase-1 (SCD1), and CD36 expression, quantified via qRT-PCR and western blotting. The correlation was analyzed using a luciferase reporter assay. Cell proliferation, migration, and invasion were analyzed using CCK-8, wound healing, and transwell assays, respectively. Oil Red O staining and flow cytometry were used to detect lipids. Triglycerides and cholesterol levels were analyzed using a reagent test kit. CY3-labeled oleic acid transport was analyzed using an oleic acid transport assay. Tumor growth and metastasis were detected in vivo in a xenograft mouse model.RESULTS:MiR-3180 suppressed de novo fatty acid synthesis and uptake by targeting the key lipid synthesis enzyme SCD1 and key lipid transporter CD36. MiR-3180 suppressed HCC cell proliferation, migration, and invasion in an SCD1- and CD36-dependent manner in vitro. The mouse model demonstrated that miR-3180 inhibits HCC tumor growth and metastasis by inhibiting SCD1- and CD36-mediated de novo fatty acid synthesis and uptake. MiR-3180 expression was downregulated in HCC tissues and negatively correlated with SCD1 and CD36 levels. Patients with high miR-3180 levels showed better prognosis than those with low levels.CONCLUSIONS:Our investigation indicates that miR-3180 is a critical regulator involved in de novo fatty acid synthesis and uptake, which inhibits HCC tumor growth and metastasis by suppressing SCD1 and CD36. Therefore, miR-3180 is a novel therapeutic target and prognostic indicator for patients with HCC.

MiR-34a Inhibits Lymphatic Metastasis Potential of Mouse Hepatoma Cells

Mir-200A Suppresses Cell Growth and Migration by Targeting MACC1 and Predicts Prognosis in Hepatocellular Carcinoma.

MicroRNA-449a Suppresses Hepatocellular Carcinoma Cell Growth Via G1 Phase Arrest and the HGF/MET C-Met Pathway

Mir-194 is A Marker of Hepatic Epithelial Cells and Suppresses Metastasis of Liver Cancer Cells in Mice

microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma

Mir-17-5p and Mir-20A-5p Suppress Postoperative Metastasis of Hepatocellular Carcinoma Via Blocking HGF/ERBB3-NF-κB Positive Feedback Loop

MicroRNA-24-1 Suppresses Mouse Hepatoma Cell Invasion and Metastasis Via Directly Targeting O -Glcnac Transferase

Microrna-29b Suppresses Tumor Angiogenesis, Invasion, and Metastasis by Regulating Matrix Metalloproteinase 2 Expression

Microrna-34c Targets Tgfb-Induced Factor Homeobox 2, Represses Cell Proliferation And Induces Apoptosis In Hepatitis B Virus-Related Hepatocellular Carcinoma

Mir-9 Inhibits the Metastatic Ability of Hepatocellular Carcinoma Via Targeting Beta Galactoside Alpha-2,6-sialyltransferase 1

Mir-192, A Prognostic Indicator, Targets the Slc39a6/Snail Pathway to Reduce Tumor Metastasis in Human Hepatocellular Carcinoma

MicroRNA-148a Suppresses the Epithelial-Mesenchymal Transition and Metastasis of Hepatoma Cells by Targeting Met/Snail Signaling.

Mir-142-3p Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Regulating HMGB1 Gene Expression.

Inhibition of Lymphangiogenesis: A Protective Role of microRNA 146a‐5p in Breast Cancer

MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma.

MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma.

Microrna-363-3p Inhibits Hepatocarcinogenesis By Targeting Hmga2 And Is Associated With Liver Cancer Stage

Mir-1188 at the Imprinted Dlk1-Dio3 Domain Acts As A Tumor Suppressor in Hepatoma Cells

Mir-146a Suppresses Hepatocellular Carcinoma By Downregulating Traf6

MiR-3180 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Targeting Lipid Synthesis and Uptake.

Advances in research on the role and mechanism of microRNAs in hepatic carcinogenesis